Similarly, in the E0771 tumor-bearing mouse model, the application of IL-2 neutralizing antibodies reduced the increase in Tregs induced by BTG2 knockout and mitigated the CTL functional inhibition caused by BTG2 deficiency (Supplementary Figures S4F-H). This evidence concerns the gene BTG2 and neoplasm.